融資意外地拯救了被遺棄的干細胞試驗

1、融資意外地拯救了被遺棄的干細胞試驗作者:日期：Fundingwindfa11andmarkstemcellrescuesabandonedstemce1ltrialtwoand-a-ha1fyeaCaliforniaialaftissputteringbacker?ltwasabandonedlibycompanythatfreshsetofpackedwithstartedchallenit.Butitnowges,includtdelpofwhetherivedfnervesspina1abruptly1);saidwantedntscellromcompetitors.?Theshuma

2、nembryonicto-cordregrowininjury.in2011byatinstead.oftheedthetimeofocuAsteMen1trCalifornIRM),Buttreat7thatssibithatonsNlow,newia129iatheingtrialacesfieldaimsstem?cellsathattoiscancaItGersessstoppedonofNature479,9;itveralcompa?promisingcancertmeiasPawithMayBiotherapenyuticsafrInstitstate'ieldAster

3、iassinlitybiotechnoforlogyp1ansUS$14.3-millionomthe,a1resurr?grantsoectthatitreceivutehasfirstforRegenerativestem-cell-funmovedonsinpatientindingce2010,Medicine?(Cagency.Geronhasoftreatedspc12heritedinal-coradifferentompanypatientstypeoisdino?startamoreeffectiveness.Andadvancedanothei1stemofGermanto

4、wn,receivedregulatorytobeginhumanron'shumantrialappestsce11sButreing?concernsthecellscompanderivedgulatorsaboutthebeingireportednaleclin0rdcalcou1dnolinjury.ngeranthethenltherapyy小。Newark,asafeStemCells,CalifoarniastemcetrialtentrantMary1and,rovalinofitswasfromhaltedthehumanitpuritymplantseeinga

5、ed,sofratststudies.Theteratomastll,hystudyanditisyeartotothe?fieldpltanstJanuary2013stem-cellproduct.stNeura?Gefirstapprovedto?usembryonicstem?cetwice,oncecitndandmicroscopihathadpredictabi1ityagainaftercystsin7thebeentreatedworrywasthattheuncontrol1edgrowthsofthein?prcyststhatcanformfromfearedsidee

6、ffectofhatthegrowthswere6mbryonictreatment.notteratostemcells,aGeronlatersaid?tmas,andthe?USFoodandDrugAdministrationa1lowedthetrialtoproceed.Butafterinjectingthecel1sinto?fiveofthetenintendedpatients,thecompanysaid1.?Geronchiefterias,hatithadrunfounderMichaelexecutwhichreeeitlastpatineck,willyear.e

7、ntsusingthenosestoseensation?orfuefiviascordrepooutofmoneyforWestandformeriveThomasOkarmathenforboughtGeronb?sstem-cell?hThefctthetriamedAserapcompanyplanthspinal-cord1owdoseofeatdiffthetherentsfirstto?treatthdamage?inthestempeoplewitthce1ls;hhigher?depatientscontinuesdamageatrtedthatprevtotchestnon

8、eserioussideeffectsordeve1opedimmuneResearcherssayformepeofsusedgicallyrGeroncellbyimp1xedmyelinatedinouslacklevel.offromerapythetrytreahadcanunkrestoreanyse1imbs.?Thtedby?Geron,whomAsterOn22May,Asteriasthosefivehadthetreatmentresponsestoit.experiencedthattrialdifferentStemCellsantedembrythecontiisi

9、mportantfromthefetandNeuralstenuationbecause0nleing1ialswhenmature.vitrocells,Theothertowhstemgrowinm.ce1ichinsu1ofittheuses?aty-derived?oneGeronsurlsthat?hadbeeimmatureydifferentiatfetalbrainthatproteionsinthfortheavemultialpr?populatiousdefinewhatdcellsderivedmpaniesfromatee?usingnerve?fibrepartia

10、l1efitissue,survivinneuraleld,gcirwhichmighttissueandproducemakenewsubstancesonnectis?work,b?sayscuitry.?b?Itbecausecel1lineswe，bnow?sverygooofpatients,ingantestdtedhisinvery1lsimi1heneededtoMartinMarsamakela,ahisapprneuroscienoachtisttheUniversityofCalifornia,SanDiego,whoseworkhasshownthatNeuralste

11、mriscellscandevelopintoworkingneuronsandrestore?movementtoratswithcordinjuriesintheneck.?Sti1l,someinthefieldquestionwhether?stemcellsareagoodcandidatefortreating?paralysis.Spinaltraumacandestroyarangeofcells;itcanbedifficulttoaccesstheinjury?site;anddamagecanbeverysevere.Treatingparalysis“maybeaski

12、ngalotmoreofthecellsthantheyarecapab1eofbio1ogica1ly”,saysRobertLanza,chiefscientific?officeratAdvancedCellTechnologyinMarlborough,?Massachusetts,whstem c e lls in twcompany o p ted no t t i n part bee auseichisnowtesting?Smbryo-derivedoeyediseases.?Lanzasaysthathiso?buyGeron'sstem-celltherapy?t

13、hetre a tmen t did n o t seem e f f ean i mal mod el s . So me of thescien t istsen o u g hwh o ?re v i ewedAste rias's sed c on c erns g r ant p ra b o ut theoposaltreatmtothe?CI RMt' s ?effe c tivalsoe ne sexp r en a n i m al“It woulfa n t a sticifthe cel 1wo rk,but Itwoulda 1 so b ew isen

14、 ottoets ays Lanz t ha v ea . ?Mar sal aco untersex p ectations tha t thetooce 1high, ” ls d onoto healthep e o p le ' injur e d t 小revent orte ds p i lives.o r deadth ehatsomesensatinof e e li n g some butnalHedamag ecornotefrof our peopleon; t woin t h ei rwere able towiinc o mpl e t e ly tha

15、t simp 1 y th h ealth ys prea d ing.its st u di ep rev i o u sly h a1 ower1 im b sf ee 1mo r etran s plant. Marsala sees this a sthethatthe rapy i s worki n g.you are going to se etoi mp rovereplacing one s mig hSt e mCell s ?has re ps hav e ?reco ver eandafter“Nobody is com pl e t et hese-一一.力p at

16、i e n t s ,he says. ?Chri s t oph ei ci s tat St anford ?Uni ve r si t yanothertwo?h athe?ce 1s i gnt h atc lai m ingr e co v ery r Scot t ,i n?an ethin Calif o r nia, saysthatbeforescientistscanjudgetheeffectivenessofthe?therapies,thecompaniesmustcompletetheirt r ials.But he wond ers whet herAst e

17、r ias has s u fficient 才esou r ce s t od on its promisemake go o to ?carryGeron' st h e ra p y thr ough to complet i on.Scot t no t es m illion s o f -cord and?othert h at Geron spen t h undreds of d olla r s dev elopin g spinal embr yonic-stem cell t h e r api e s, butmanaged?to tr e a t 0nlyf

18、ive people. The restart e d tria 1 ?wif acee ve n gr e aterscruti n y, and he wor ri e s?t hwould b e a huge b 1 o and policy ana 1 y sts willatifitwereha1ted,itwto?Datients.“Bioethicistswatchingcarefu1ly,"hesays.融資意外地拯救了被遺棄的干細胞試驗具有里程碑意義的干細胞試驗濺射回到生活是在被加州公司拋棄了兩年半以后開始的。但現(xiàn)在面臨的一項新的挑戰(zhàn)，包括一場充滿了競爭對手的戰(zhàn)場

19、。試驗的目的是測試來自于人類胚胎干細胞的細胞是否能幫助神經(jīng)再生在脊髓損傷的例子中。它在2011年被GeronofMenloPark,California突然中斷。該公司當時說，它想把重點放在幾種有前景的癌癥治療。哎喲，一家新公司阿斯忒瑞亞Biotherapcutics也門洛帕克市計劃復活審判，5月29日收到加州再生醫(yī)學研究所（CIRM）的14.3美元撥款，國家年代stem-cellfunding機構(gòu)。但這一領(lǐng)域已經(jīng)自2010年Geron首次治療病人，和阿斯忒瑞亞證明了不再是唯一的治療脊髓損傷的可能性。干細胞，在加州的紐瓦克的一家生物技術(shù)公司，治療12例在一個安全的不同類型的干細胞研究中，并計劃

20、今年開始一個更先進的試驗去測試有效性。和另一個進入這一領(lǐng)域，Neuralstem日耳曼敦，馬里蘭州，獲得監(jiān)管部門批準，于2013年1月開始人體試驗的干細胞產(chǎn)品。Geron公司的人體試驗是第一個被批準使用來自干細胞衍生出來的細胞。但監(jiān)管機構(gòu)暫停了兩次11,理由是對有關(guān)的純度和可預測性的擔憂后的被植入的細胞，并有公司再次報道看到在顯微鏡下囊腫大鼠脊髓已被處理，令人擔憂的是，囊腫可能是畸胎瘤-可以從胚胎干細胞，不受控制的生長。以形成治療的擔心副作用。Geron后來說這個增長并不是畸胎瘤，美國食品和藥物管理局允許實驗進行。但在注入細胞的百分之五十的病人中，該公司表示，它已為審判耗盡試驗。Geron的創(chuàng)

21、始人邁克爾西和前首席執(zhí)行官ThomasOkarma后來成立了阿斯忒瑞亞。去年收購了Geron的干細胞治療，該公司計劃首先治療三個頸脊髓損傷患者，使用低劑量的干細胞。然后它會對不同的人高劑量治療看看是否可以恢復任何在軀干或四肢的感覺或功能。先前由Geron治療的在胸線損傷水平的五個病人，現(xiàn)在繼續(xù)由Asterias跟蹤治療。在三月二十二日，Asterias稱五個人中沒有一個是在治療過程中有嚴重副作用和對它有高度的免疫應答的。研究人員稱，Geron的延續(xù)前試驗是很重要的,因為它使用一個類型的細胞不同于fetus-derived的介紹和Neura1stem使用的。Geron手術(shù)植入胚胎干細胞，誘導體外生長到成熟有髓神經(jīng)膠質(zhì)細胞，成熟時，使神經(jīng)纖維被隔離。其他公司使用部分來源于胎兒腦組織的分化細胞這可能會產(chǎn)生新的物質(zhì)，保護殘存的組織和連接神經(jīng)回路。他們的工作表明，Neura1st